Literature DB >> 15032272

Androgens and ovarian cancers.

P H Wang, C Chang.   

Abstract

Ovarian cancer is one of the most lethal malignancies in women. Numerous studies indicate that the steroid hormones have been implicated in the etiology and/or progression of epithelial ovarian cancer and support a role for androgens, including: 1) androgen receptor (AR) is present in primate ovaries at almost all stages of the menstrual cycle and involve folliculogenesis and ovulation; 2) high androgen serum levels show high risk of ovarian cancer and ovarian cancer occurring after menopause when the balance of ovarian steroid production shifts from estrogens to androgens; 3) ovarian cancer tissue shows a 90% AR positive rate and is associated with favorable outcomes; 4) androgens promote or inhibit ovarian cancer cell growth; 5) chemotherapy decreases androgen production from cancer cells. This review seeks to summarize our current understanding about the roles of androgens, AR and AR coregulators in the initiation and/or progression of ovarian cancers.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15032272

Source DB:  PubMed          Journal:  Eur J Gynaecol Oncol        ISSN: 0392-2936            Impact factor:   0.196


  10 in total

1.  The oncogenic gene fusion TMPRSS2: ERG is not a diagnostic or prognostic marker for ovarian cancer.

Authors:  Lillian Huang; Isaiah G Schauer; Jing Zhang; Imelda Mercado-Uribe; Michael T Deavers; Jiaoti Huang; Jinsong Liu
Journal:  Int J Clin Exp Pathol       Date:  2011-09-15

Review 2.  Genomic analysis of epithelial ovarian cancer.

Authors:  John Farley; Laurent L Ozbun; Michael J Birrer
Journal:  Cell Res       Date:  2008-05       Impact factor: 25.617

3.  Immunoexpression of androgen receptor in the nontumorous pituitary and in adenomas.

Authors:  Bernd W Scheithauer; Kalman Kovacs; Suzan Zorludemir; Ricardo V Lloyd; Seyda Erdogan; Jeffrey Slezak
Journal:  Endocr Pathol       Date:  2008       Impact factor: 3.943

4.  Expression and function of androgen receptor coactivator p44/Mep50/WDR77 in ovarian cancer.

Authors:  Martin Ligr; Ruzeen Rohintan Patwa; Garrett Daniels; Lorraine Pan; Xinyu Wu; Yirong Li; Liantian Tian; Zhenxing Wang; Ruliang Xu; Jingjing Wu; Fan Chen; Jinsong Liu; Jian-Jun Wei; Peng Lee
Journal:  PLoS One       Date:  2011-10-13       Impact factor: 3.240

5.  Integrative transcriptomics-based identification of cryptic drivers of taxol-resistance genes in ovarian carcinoma cells: Analysis of the androgen receptor.

Authors:  Nian-Kang Sun; Shang-Lang Huang; Hsing-Pang Lu; Ting-Chang Chang; Chuck C-K Chao
Journal:  Oncotarget       Date:  2015-09-29

6.  Progesterone acts via the progesterone receptor to induce adamts proteases in ovarian cancer cells.

Authors:  Maíra A Lima; Suély V da Silva; Vanessa M Freitas
Journal:  J Ovarian Res       Date:  2016-02-25       Impact factor: 4.234

Review 7.  Molecular Regulation of Androgen Receptors in Major Female Reproductive System Cancers.

Authors:  Sujun Wu; Kun Yu; Zhengxing Lian; Shoulong Deng
Journal:  Int J Mol Sci       Date:  2022-07-08       Impact factor: 6.208

8.  Androgen-related expression of G-proteins in ovarian cancer.

Authors:  L A Sheach; E M Adeney; A Kucukmetin; S J Wilkinson; A D Fisher; A Elattar; C N Robson; R J Edmondson
Journal:  Br J Cancer       Date:  2009-07-21       Impact factor: 7.640

9.  Lineage specification of ovarian theca cells requires multicellular interactions via oocyte and granulosa cells.

Authors:  Chang Liu; Jia Peng; Martin M Matzuk; Humphrey H-C Yao
Journal:  Nat Commun       Date:  2015-04-28       Impact factor: 14.919

Review 10.  Histone deacetylases as new therapy targets for platinum-resistant epithelial ovarian cancer.

Authors:  Dmitri Pchejetski; Albandri Alfraidi; Keith Sacco; Heba Alshaker; Aun Muhammad; Leonardo Monzon
Journal:  J Cancer Res Clin Oncol       Date:  2015-11-11       Impact factor: 4.553

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.